Loading...
VALN logo

Valneva SEInforme acción NasdaqGS:VALN

Capitalización bursátil US$635.1m
Precio de las acciones
n/a
1Y-25.5%
7D-3.3%
1D-0.4%
Valor de la cartera
​
Ver

Valneva SE

Informe acción NasdaqGS:VALN

Capitalización de mercado: US$635.1m

Valneva (VALN) Resumen de Acciones

Valneva SE, empresa especializada en vacunas, desarrolla, fabrica y comercializa vacunas profilácticas para enfermedades infecciosas con necesidades no cubiertas. Saber más

Análisis fundamental de VALN
Puntuación del snowflake
Valoración2/6
Crecimiento futuro6/6
Rendimiento pasado0/6
Salud financiera3/6
Dividendos0/6

Recompensas

Se prevé un crecimiento anual de los beneficios de 71.69%

Análisis de riesgos

No se han detectado riesgos en VALN a partir de nuestros controles de riesgos.

VALN Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW439,321 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
B
BlackGoat
R
RockeTeller
I
Investingwilly
D
davidlsander
439,321 investors already sharing narratives
View all narratives

Competidores de Valneva SE

Historial de precios y rendimiento

Resumen de las cotizaciones máximas, mínimas y variaciones del Valneva
Precios históricos de las acciones
Precio actual de la acción€6.66
Máximo en las últimas 52 semanas€12.23
Mínimo de 52 semanas€4.75
Beta1.37
Cambio en 1 mes20.00%
Variación en 3 meses24.37%
Cambio de 1 año-25.50%
Variación en 3 años-52.12%
Variación en 5 años-75.56%
Variación desde la OPV-76.51%

Noticias y actualizaciones recientes

Recent updates

Seeking Alpha • Aug 26

Valneva Outlook: Safety Blow To Ixchiq And Valuation Concerns

Summary The FDA suspended Ixchiq’s US license over safety concerns. This also endangers its stockpiling revenue with government contracts and near-term growth. Still, VALN’s revenue remains anchored by Ixiaro and Dukoral. A recent outbreak boosted Ixchiq Q2 revenues, so it’s not a dead blow to the company. VALN now looks forward to VLA15, which is the only late-stage Lyme vaccine. We should get its Phase 3 readout by year-end 2025. Still, now VALN’s valuable seems somewhat expensive in light of its renewed regulatory risks. Management left their guidance intact, but I’m skeptical. Thus, after a substantial rally since my previous article on VALN, I feel it’s fair to take profits and re-rate VALN down to a “Hold”. Read the full article on Seeking Alpha
Seeking Alpha • Apr 16

Valneva SE: Initiating Hold Rating Based On Potentially Limited Upside

Summary We initiate a Hold rating on Valneva SE stock due to steady cash flows and promising pipeline but significant clinical and commercial uncertainties. Valneva's stock trades at $6.29 with low trading volume; key catalysts include late 2025 data readout for Lyme disease vaccine VLA15. Financially, Valneva reported €163.3 million in revenue for 2024 with positive cash flow, extending the runway into late 2026. Significant risks include clinical delays, underperformance of vaccines, and potential cash runway strain, warranting a cautious Hold rating. Read the full article on Seeking Alpha
Seeking Alpha • Jan 23

Valneva Is A 'Buy' As A First-Mover In Chikungunya

Summary Valneva's Ixchiq is the first and only approved Chikungunya vaccine in the US, Canada, and EU. Ixiaro is for Japanese encephalitis, and it’s today VALN’s main revenue contributor. But its near term growth potential lies with Ixchiq. The main risks with VALN are related to Ixchiq’s rollout and cash runway of 4.9 quarters. It’s also a thinly traded stock, which makes it prone to volatility. Still, VALN trades at cheap valuation multiples relative to its peers, and I believe its growth potential is not yet fully priced in. VALN believes it can reach profitability by 2027, so I do believe there’s a good long-term outlook, which is why I give it a “Buy” rating at these levels. Read the full article on Seeking Alpha
Seeking Alpha • Sep 26

Valneva seeking a partnership for next-gen COVID-19 vaccine

French biotech Valneva SE (NASDAQ:VALN) announced Monday that the company is in discussions with a partner to secure funding to develop a second-generation COVID-19 vaccine. Previously, the biotech had said it would invest further in the second-generation vaccine if funding or commitments for funding materialize in Q3 2022. “As we are near the end of the third quarter 2022, we are engaged in active discussions that are likely to continue into the coming months,” Chief Executive Thomas Lingelbach remarked, noting plans to share updates if the discussions lead to an agreement. VALN has already secured European and WHO nod for its inactivated whole-virus COVID-19 vaccine, VLA2001 targeted at the original coronavirus strain. The company said the talks are underway with governments and other regulators to deliver the remaining inventory to global markets in the next twelve months. Further clinical readouts for the vaccine, notably on its booster effect as a heterologous dose, are also expected in Q4 2022. In August, VALN shared heterologous booster results for VLA2001 following initial vaccination with AstraZeneca (AZN) COVID-19 vaccine.
Seeking Alpha • Aug 29

Valneva shows booster effect of COVID shot against AstraZeneca vaccine

Citing new data from a late-stage study, French biotech Valneva SE (NASDAQ:VALN) announced Monday that the company's COVID-19 vaccine as a booster provided similar protection to AstraZeneca's (AZN) rival COVID-19 vaccine. The data from the Cov-Compare indicated that nearly two months after the primary immunization neutralizing antibody titers generated by the vaccine VLA2001 were non-inferior to AZN's shot, ChAdOx1-S. In addition, data from a section of trial subjects indicated that VLA2001 generated a broad-based T-cell response for approximately six months after primary vaccination (up to Day 208). The EU-approved vaccine was well tolerated and demonstrated a favorable safety profile up to Day 208, VALN added. The U.S. biotech Dynavax Technologies (DVAX) has partnered with Valneva (VALN) to deliver the CpG 1018 adjuvant used in the vaccine. In June, VALN won EU approval for the vaccine for primary vaccination in those aged 18 – 50.
Seeking Alpha • Aug 15

Valneva launches up to $75M at-the-market ADS offering program

Valneva (NASDAQ:VALN) entered in a new financing program to offer and sell, including with unsolicited investors who have expressed an interest, a total gross amount of up to $75.0M of American Depositary Shares, each ADS representing two of the company’s ordinary shares. To the extent that ADSs are sold pursuant to the ATM Program, the company currently intends to use the net proceeds together with its existing cash and cash equivalents, primarily for research and development of the company’s product candidates, working capital and other general corporate purposes, at the company’s discretion. The new ordinary shares to be sold in the form of ADSs would be issued in one or more offerings at market prices of the ADSs at the time of pricing of the considered capital increase. The new ordinary shares will be admitted to trading on the regulated market of Euronext in Paris and the issued ADSs will trade on the Nasdaq Global Select Market.
Seeking Alpha • Aug 08

Valneva: Vaccine Business, Catalysts Ahead, And Pfizer's Lyme Love

Valneva is a specialty vaccines company with an ongoing travelers vaccine business. Two major catalysts are around the corner: a BLA for chikungunya vaccine and a Phase 3 trial for the world’s only Lyme vaccine candidate. The company is trading near the low end of its 52-week range, with Pfizer having recently taken an 8.1% stake. Earnings, due August 11, 2022, may be interesting as they may reflect a Covid-unwinding world. The caveat is whether the market correctly appraised the future of its Covid vaccine. Thesis Valneva (VALN) is a French specialty vaccines company which has not been covered on Seeking Alpha after its Nasdaq IPO, even though it sports a market cap of $1.1 billion. It has operating sites all over the world, four of which in Europe and one in both Canada and the US, and has +750 employees worldwide. It has an ongoing travelers health business which I believe may report good results in the coming quarter, probably also with R&D expenses for the quarter reduced. VLA2001, Valneva’s inactivated Covid-vaccine which has strong efficacy across different variants, a good safety profile and booster potential, is currently suffering from an oversupply of Covid-vaccines, at least in the Western world. There may be an occasion here in the longer term, as a shift towards better vaccines than those currently used occurs. In the second half of 2022, Valneva will file for a biologics license application ((BLA)) for VLA1553, its Chikungunya vaccine candidate. This vaccine candidate has fast-track designation in the US, prime designation in the EU, and is eligible for a priority review voucher. VLA1553 has shown excellent safety and immunogenicity results and seems best placed to become the go-to vaccine for this disease. In the third quarter of 2022, Valneva will initiate a Phase 3 trial for VLA15, the world’s only Lyme vaccine candidate, which is again shown to be safe and efficacious. Pfizer (PFE) co-develops this vaccine, has provided serious funding, will pay more as milestones progress, and has just recently taken an 8.1% stake in Valneva. I see a buying opportunity here, with two important catalysts ahead, i.e. the BLA for the chikungunya vaccine and the Phase 3 trial initiation for the Lyme vaccine candidate. The fact that Pfizer saw the interest in the Lyme vaccine adds to my conviction. With about €300 million in the bank, I believe the market’s current valuation of Valneva is too low. I do see one caveat, and that would be that the market hasn’t fully discounted poor revenue coming from Valneva’s Covid vaccine. The current share price The company trades both on Euronext and on the Nasdaq, with much less liquidity on the latter. On Euronext, it trades under the ticker 'VLA', with a year-high of €29.7 and a year-low of €7.26. Its one-year chart is as follows. Trading on Euronext is more liquid. Valneva stock price chart Euronext (Google) On the Nasdaq, where the company trades under the ticker 'VALN', its yearly trading range is in between $67.84 and $13.71, with the company now trading around $20. Contrary to Euronext, there is little liquidity on the Nasdaq. There has been volatility in the stock price lately due to negative sentiment surrounding the commercial viability of the Covid vaccine program on the one hand, and positive sentiment relating to the recent €90.5 million stake of Pfizer in Valneva on the other. I will cover Valneva’s portfolio below as a function of each asset’s maturity in the business. I see most potential in both the chikungunya and Lyme disease candidates. Contrary to its Covid-vaccine, I believe those vaccines will not face serious competition, if any, once approved. Hence, I am looking at this company in part as a biotech company with a high-value late-stage pipeline, a fully operational manufacturing and commercial team, and a recovering ongoing business. Valneva’s ongoing business: traveler health portfolio and third-party distribution Valneva’s Traveler Health portfolio includes two vaccines, Ixiaro/Jespect and Dukoral, and encompasses vaccines for those traveling to other countries. Ixiaro, commercialized under the name Jespect, is a vaccine for Japanese encephalitis. Dukoral is a vaccine for the cholera and prevention of diarrhea resulting from an enterotoxigenic E. Coli bacteria. This business, covering approvals in most countries in the Western world, had been heavily impacted by travel restrictions and Covid-related lockdowns, mostly in 2020. Revenues declined from $130 million in 2019 to $66 million in 2020 and $63 million 2021, which still saw an impact from the pandemic. US soldiers travel too, and Valneva in fact derives quite some revenue from its long-standing relationship with the US government. The US military has an ongoing 3-year supply contract with Valneva for Ixiaro, and has been using that vaccine for more than 10 years already. The total minimum value of this contract is $118 million. I expect Valneva to report good numbers here for the second and third quarter of 2022. Valneva also commercializes third-party products such as Moskito Guard, Encepur, Flucelvax Tetra, Fluad, Kamrab and Rabipur, amounting to $15.4 million in 2021. It also has some minor other revenues. VLA2001, an inactivated COVID-19 vaccine VLA2001 is an inactivated virus vaccine which has shown robust efficacy and safety against different variants. It applies the same technology as Ixiaro’s, and consists of inactivated Covid-19 particles with preservation of the native structure of Covid-19’s spike-protein. It can be stored at cold chain temperatures (2-8° Celsius), can be used as primary vaccination or as a booster, and is suitable for routine immunization in the longer term. The Phase 3 trial results showed superiority in neutralizing antibody levels and a better safety profile compared to AZD1222, another EMA-approved vaccine. It has received standard marketing authorization in the EU, conditional marketing authorization in the UK, and emergency use authorization in Bahrain and the UAE. Q3 2022 should see Valneva readout its booster data, which I do not expect the market to react to. Here comes the catch though. Due to oversupply of vaccines in the Western world at this, this vaccine has yet to turn into a commercial success. The UK government had terminated its contract to order several million doses in 2021, which has led to a +$200 million settlement agreement in that year, which led the company to report total revenue of €348.1 for that year, compared to €110.3 million in 2021. I do add that 2020 and 2021 were weak years as the company’s travelers health portfolio revenue was seriously impacted by Covid. In 2019, revenue from the travelers health portfolio had been €129.5 million. The EU has recently expressed its wish to terminate its supply agreement with Valneva to supply up to 60 million doses over a period of two years, which led the stock to sell-off to its year-low in June 2022. The company is in talks with the EU about a remediation plan, as several EU countries have expressed their wish to receive the vaccine. I have seen an analyst write that Valneva may accept a ‘best-we-can-do’ offer to reduce stock inventories. Valneva has nonetheless clearly stated that, if volume indications would be too low, commercialization would not be sustainable. In that sense, I believe the company will have to revise its sales guidance expressed for 2022, but I believe the market has taken that into account. In the longer run, as the world may be ready for better and longer-lasting vaccines than the ones that are currently mainstream, this vaccine may attract business. VLA1553, the chikungunya vaccine candidate VLA1553 is one of three chikungunya vaccine candidates in development, probably best-in-class and furthest-progressed. Chikungunya is carried by mosquitoes in tropical and sub-tropical environments such as the Americas, India, and Thailand. It is prone to cause outbreaks among the population with a severe economic impact. Morbidity is low, but the inflammatory burden and persistent joint pain have a debilitating impact. VLA1553 overview slide (Valneva corporate presentation) The Phase 3 trial results showed outstanding immunogenicity and led to protective chikungunya neutralizing antibody titers in 98.5% of participants 28 days after single-dose administration. That 98.5% seroprotection rate exceeded the bar of 70% that had been agreed with the FDA. VLA1553 has basically been racking up regulator’s favoritism, with fast-track and prime designation respectively by the FDA and the EMA, and breakthrough therapy designation by the FDA in July 2021. Valneva is now likely to receive a priority review voucher, as sponsor of the first chikungunya vaccine to be approved in the US. Valneva would include VLA1553 in its travelers health portfolio with approval in the US and the EU underway. It has also entered into an agreement with the Brazilian ‘instituto butantan’ to commercialize this vaccine for less developed countries. Valneva is about to file for a BLA any time now, as it had been announced for mid-2022. I believe this could be a substantial catalyst for this drug candidate. Upon approval, launch can be expected soon after, with the plus here that Valneva has its commercial network set up already. In a global market which is to exceed $500 million by 2032, it can capture that market upon approval and establish its go-to position for years to come. I have read an analyst forecast risk-adjusted peak sales of €260 million by 2028. The above means that upon approval, this business has the potential of tripling the current sales revenue over time. VLA15, the Lyme disease vaccine candidate VLA15 is the biggest horse in the stable in my eyes, as the only Lyme vaccine candidate in the world, with outstanding Phase 2 data, which came in different sets of data over different studies, and huge Pfizer backing/involvement. Lyme disease is commonly known to most people. It is caused by the Borrelia burgdorferi bacteria, is transmitted by ticks and highly present in several regions of the Western world, where it expands more and more due to climate change. Lyme disease incidence slide (Valneva corporate presentation) Most patients recover, but 10-20% have persistent and sometimes disabling issues such as ongoing fatigue. There is currently no vaccine for Lyme disease available in the world, and although antibiotic treatments may provide relief, these generally come too late because detection of the disease is slow, and the therapeutic window passes. VLA15 has shown strong immune responses across 6 different serotypes. In April 2022, Valneva has reported results of its phase 2 pediatric study showing strong immunogenicity and an outstanding safety profile. These results build on earlier successful Phase 2 results, which is perhaps why the market has not given them much attention, if any. The upcoming catalyst here is the initiation of a phase 3 trial the second half of 2022, the results of which could be expected by year-end 2023. In the US and Europe combined, about 700,000 people each year are diagnosed with Lyme disease, with this number on the rise due to climate change. Pfizer and Valneva have a co-development and co-commercialization partnership here, with development-costs being split 60/40 for Pfizer and Valneva, respectively, and Valneva eligible for milestone payments. Of these milestone payment, $168 million are still to be paid. Initiation of the Phase 3 study, which is for any time now, will lead to a $25 million payment. The Pfizer involvement should ensure perfect marketing and commercialization potential. The most recent terms of the royalty agreement, as recently revised, are tiered royalties ranging from 14% to 22%. Add to that, Valneva is eligible for up to $100 million in milestone payment from Pfizer based on cumulative sales. I will also add to that, Pfizer is flush with cash and apparently on a buying spree. Latest rumors, as reiterated in this Seeking Alpha editor coverage on prognosis for the biotech sector in the current quarter, include rumors of Pfizer being in talks to buy Global Blood Therapeutics (GBT) in a $5 billion deal. In my earlier Cardiff Oncology (CRDF) coverage, I had recalled how earlier Pfizer equity investments led to buyouts. An 8.1% stake of Pfizer may bode well here, but I have difficulties to believe that would be a short-term scenario as parties have just revised their deal. I’ll add that Pfizer seems most interested in Valneva’s Lyme business, which I assume could not be included in Valneva’s travelers health portfolio. If one would assume a 400-million-person worldwide market with 3% penetration (i.e. 12 million), and pricing of $100 in the US and €50 in the EU which would be equally split between the two main markets, one arrives at sales numbers of $1.2 billion and €600 million, respectively. Assuming royalties to be around 18% (the middle of 14% and 22%), revenues would be $216 million for the US and €108 million for the EU. These are only vague estimates at this stage, as pricing is unknown and the concrete markets are unexplored, but they do give an idea of the value-driving potential here. Pfizer is seeing it, and again, there is no competition for this vaccine in the pipeline. First quarter 2022 results and second quarter expectations The results reported by Valneva for Q1 2022 were about the same as those reported for the year before. Total revenue was €21.8 million compared to €23.2 million in 2021, with product sales of €16.2 million compared to €16.1 million in 2021, and with first COVID-19 vaccine sales of €3.8 million. A total of €5.6 million were derived from other revenues, compared to €7.1 million in 2021. As Valneva’s business had been severely impacted by Covid-measures, I expect to see an uptick in business results for the coming quarter, as people are resuming travel again similar to pre-pandemic times to countries where the vaccines in the traveler’s health portfolio are of use. Valneva highlights in its corporate presentation that this business represented $130 million in 2019 when it was growing strongly (slide 18), and is a key asset for the future. Guidance in the Q1 results on May 5, 2022, was that Valneva expected its 2022 revenues to be within the range announced in February, namely €430 million to €590 million. I expect this guidance is no longer applicable in light of the recent termination or termination discussions with regards to the Covid vaccine, both in the UK and in the EU. I do believe the market has already discounted the future revision of that guidance, which one can see in the share price dip right after the Covid-update the company issued on June 10, 2022. Already for the first quarter of 2022, R&D costs were reduced to €20.7 million, where they were still €27.7 the year before. This was mainly attributable to ending of the Phase 3 trial for chikungunya and lower investments for the Covid-vaccine. I don’t expect to see any major R&D costs for the second quarter of 2022, as the Phase 2 trials for Lyme disease have now also ended. The reduction of R&D expenses for Q2 2022 that I expect may also have a considerable impact on operating and EBITDA loss compared to previous quarters. For Q1 2022, Valneva’s operating loss was €18.4 million versus €31.1 million in Q1 2021. Q1 2022 adjusted EBITDA loss was €12.7 million compared to €28.3 million in Q1 2021. Financials These were Valneva’s 2021 financial results as reported on March 24, 2022. Valneva 2021 financial results (Valneva Full Year 2021 reporting) Total revenues in 2021 were €348.1 million, compared to €110.3 million in 2020, but of that €348.1 million, €253.3 million was attributable to a settlement under the terminated UK agreement. Revenues from normal business, affected by Covid, were €94.8 million. As these were $130 million in 2019 and were apparently on the rise, I expect Valneva to do better here in Q2 2022 than compared to last quarter or last year’s second quarter. Valneva is flush with cash and will be so for the foreseeable future. Its cash position end of March 2022 €311.3 million. In April 2020, Valneva entering into an R&D agreement with Pfizer for the Lyme vaccine candidate, which led to an upfront payment of $130 million in June 2020. Pfizer is due to pay an additional $178 in development milestones, among which $25 million when the vaccine candidate enters Phase 3 trials. In May 2021, Valneva picked up $107.6 million as a result of a global Offering and Nasdaq listing, which was followed by an additional global offering worth $102 million. The collaboration agreement with Pfizer has been adapted in June 2022, with Pfizer taking an equity investment in Valneva of 8.4% for a total of $90.5 million, and with parties agreeing a slightly different royalty split. Finally, a financing arrangement with US healthcare funds Deerfield and Orbimed led to the availability of an additional $40 million in April 2022. A fair value for Valneva’s business potential As mentioned above, given its pipeline, I am looking at Valneva as an ongoing business with an even bigger pipeline.
Seeking Alpha • Jul 20

Valneva agrees to cut COVID vaccine supplies to EU

The European Commission announced an agreement with Valneva (NASDAQ:VALN) (OTCPK:INRLF) (OTC:VNVLF) on Wednesday that would sharply reduce the French biotech’s COVID-19 vaccine deliveries to the region this year. In late June, the commission approved Valneva’s (VALN) COVID-19 vaccine named VLA2001, which is based on the CpG 1018 adjuvant developed by U.S. biotech Dynavax Technologies (DVAX). In November, Valneva (VALN) agreed to deliver up to 60M doses of its vaccine to the region, including 27M this year. However, the delay in its approval has prompted the EU to seek amendments to the deal as vaccination rates plummeted across the region. Per the revised deal, the EU has agreed to procure only 1.25M doses of the vaccine in August and September. The agreement also includes an option to buy additional 1.25M doses before the year-end. Read: Valneva (VALN) has obtained the support of rival COVID shot maker Pfizer (PFE) for the development of its Lyme disease vaccine candidate, VLA15, which is set to enter late-stage studies in 3Q 2022.

Rentabilidad de los accionistas

VALNUS BiotechsMercado US
7D-3.3%-5.3%-1.0%
1Y-25.5%37.0%14.1%

Rentabilidad vs. Industria: Los resultados de VALN fueron inferiores a los de la industria US Biotechs, que obtuvo un rendimiento del 37% el año pasado.

Rentabilidad vs. Mercado: VALN obtuvo unos resultados inferiores a los del mercado US, que fueron del 14.1% el año pasado.

Volatilidad de los precios

Is VALN's price volatile compared to industry and market?
VALN volatility
VALN Average Weekly Movement9.0%
Biotechs Industry Average Movement9.6%
Market Average Movement6.9%
10% most volatile stocks in US Market15.3%
10% least volatile stocks in US Market2.9%

Precio estable de las acciones: VALN no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.

Volatilidad a lo largo del tiempo: La volatilidad semanal de VALN (9%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

FundadaEmpleadosCEOPágina web
1998620Thomas Lingelbachvalneva.com

Valneva SE, una empresa especializada en vacunas, desarrolla, fabrica y comercializa vacunas profilácticas para enfermedades infecciosas con necesidades médicas no cubiertas. Ofrece IXIARO, una vacuna inactivada contra la encefalitis japonesa derivada de un cultivo de células Vero, indicada para la inmunización activa contra la encefalitis japonesa; DUKORAL, una vacuna oral para la prevención de la diarrea causada por Vibrio cholerae o por la bacteria Escherichia coli enterotoxigénica productora de toxina termolábil; e IXCHIQ/ VLA1553, una vacuna viva atenuada de dosis única para la prevención de la enfermedad causada por el virus del chikungunya. La empresa también desarrolla VLA15, una vacuna candidata contra la Borrelia, la bacteria causante de la enfermedad de Lyme; S4V2, una vacuna candidata bioconjugada tetravalente contra la shigelosis, una infección diarreica causada por la bacteria Shigella; VLA1601, una vacuna candidata dirigida contra el virus del Zika, una enfermedad viral transmitida por mosquitos; VLA1554, una vacuna candidata dirigida contra el metapneumovirus humano; VLA84, una vacuna candidata destinada a la prevención de la infección primaria sintomática por Clostridium difficile; PF-07307405, una vacuna candidata para prevenir los casos de enfermedad de Lyme en personas de cinco años o más, y VLA2112, una vacuna candidata para tratar a pacientes con el virus de Epstein-Barr.

Resumen de fundamentos de Valneva SE

¿Cómo se comparan los beneficios e ingresos de Valneva con su capitalización de mercado?
Estadísticas fundamentales de VALN
Capitalización bursátilUS$635.09m
Beneficios(TTM)-US$182.80m
Ingresos (TTM)US$165.74m
3.8x
Ratio precio-ventas (PS)
-3.5x
Ratio precio-beneficio (PE)

¿Está VALN sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de VALN
Ingresos€142.94m
Coste de los ingresos€202.59m
Beneficio bruto-€59.65m
Otros gastos€98.00m
Beneficios-€157.65m

Últimos beneficios comunicados

Jun 30, 2026

Próxima fecha de beneficios

Nov 12, 2026

Beneficios por acción (BPA)-0.83
Margen bruto-41.73%
Margen de beneficio neto-110.29%
Ratio deuda/patrimonio226.9%

¿Cómo se ha desempeñado VALN a largo plazo?

Ver rendimiento histórico y comparativa

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2026/09/11 06:28
Precio de las acciones al final del día2026/09/11 00:00
Beneficios2026/06/30
Ingresos anuales2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Valneva SE está cubierta por 16 analistas. 10 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Vladimira UrbankovaErste Group Bank AG
Simon ScholesFirst Berlin Equity Research GmbH
Rajan SharmaGoldman Sachs